<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04536649</url>
  </required_header>
  <id_info>
    <org_study_id>SPHIC-TR-HNCNS-2020-45</org_study_id>
    <nct_id>NCT04536649</nct_id>
  </id_info>
  <brief_title>Proton and Heavy Ion Beam Radiation vs. Photon Beam Radiation for Newly Diagnosed Glioblastoma.</brief_title>
  <official_title>Proton and Heavy Ion Beam Radiation Versus Photon Beam Radiation for Newly Diagnosed Glioblastoma: A Multi-center Prospective Phase 3 Randomized Control Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Proton and Heavy Ion Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Proton and Heavy Ion Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center prospective phase 3 clinical trial to explore the efficacy and side&#xD;
      effects of standard-dose photon radiation versus standard-dose proton radiation versus carbon&#xD;
      ion boost plus standard proton radiation for newly diagnosed glioblastoma. The patients&#xD;
      enrolled will be randomly allocated with 1:1:1 to three group: Control Group, standard-dose&#xD;
      photon radiotherapy; Study Group A, standard-dose proton radiotherapy; Study Group B,&#xD;
      standard-dose proton radiotherapy plus induction carbon-ion radiotherapy boost. The primary&#xD;
      endpoint is overall survival (OS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-center prospective phase 3 clinical trial will enroll 369 patients with newly&#xD;
      diagnosed glioblastoma. Patients will be randomly allocated with 1:1:1 to three groups:&#xD;
      Control Group, standard-dose photon radiotherapy (60 Gy); Study Group A, standard-dose proton&#xD;
      radiotherapy (60 GyE); Study Group B, standard-dose proton radiotherapy (60 GyE) plus&#xD;
      induction carbon-ion radiotherapy boost (15GyE/3F). All patients will receive concurrent and&#xD;
      adjuvant temozolomide according to the Stupp protocol. The primary endpoint is overall&#xD;
      survival (OS). The secondary endpoint is progression-free survival, side effect and quality&#xD;
      life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From the pathological confirmation to death, a median of 3 years.</time_frame>
    <description>The interval from randomization to death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>From randomization to tumor progression, with a median of 3 years.</time_frame>
    <description>The interval from randomization to progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicities</measure>
    <time_frame>From start to 12 months after completion of radiotherapy.</time_frame>
    <description>The scores of toxicities are based on CTCAE criteria, which refers to Common Terminology Criteria for Adverse Events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recognitive Function</measure>
    <time_frame>From initiation of radiotherapy to 12 months after completion of radiotherapy.</time_frame>
    <description>The assessment of recognitive function is based on MMSE criteria, which refers to Mini-Mental State Examination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life Quality</measure>
    <time_frame>From initiation of radiotherapy to 12 months after completion of radiotherapy.</time_frame>
    <description>The assessment of life quality is based on ADL criteria, which refers to Activities of Daily Living.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">369</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Standard-dose Photon Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive standard-dose photon radiation (60Gy/30F for high-risk area) with concurrent temozolomide (75mg/m2, qd), adjuvant temozolomide (150-200mg/m2, qd, D1-5, 28d/cycle)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard-dose Proton Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive standard-dose proton radiation (60GyE/30F for high-risk area) with concurrent temozolomide (75mg/m2, qd), adjuvant temozolomide (150-200mg/m2, qd, D1-5, 28d/cycle).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard-dose Proton Radiotherapy plus Carbon-Ion Boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive carbon-ion radiation boost (15GyE/3F for residual lesion) priot to standard-dose proton radiation (60GyE/30F for high-risk area) with concurrent temozolomide (75mg/m2, qd), then adjuvant temozolomide (150-200mg/m2, qd, D1-5, 28d/cycle).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Multimodal brain imaging-guided radiotherapy using different beams</description>
    <arm_group_label>Standard-dose Photon Radiotherapy</arm_group_label>
    <arm_group_label>Standard-dose Proton Radiotherapy</arm_group_label>
    <arm_group_label>Standard-dose Proton Radiotherapy plus Carbon-Ion Boost</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt; 18 years old and &lt;80 years old&#xD;
&#xD;
          -  Pathologically confirmed newly-diagnosed GBM&#xD;
&#xD;
          -  Redisual lesion after subtotal resection, partial resection, or biopsy&#xD;
&#xD;
          -  No dissemination or metastasis in the spinal canal, single lesion, supratentorial&#xD;
             lesion&#xD;
&#xD;
          -  ECOG score 0-1&#xD;
&#xD;
          -  Sign the informed consent form before starting the research&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No pathological confirmed evidence of GBM&#xD;
&#xD;
          -  Multiple lesions or distant spread indicated by imaging studies&#xD;
&#xD;
          -  Receive conventional photon/proton/carbon ion radiation therapy on the head&#xD;
&#xD;
          -  Received intracranial radioactive particle implantation&#xD;
&#xD;
          -  A history of malignant tumors or multiple primary tumors (except skin basal cell&#xD;
             carcinoma)&#xD;
&#xD;
          -  Positive pregnancy test for women of childbearing age&#xD;
&#xD;
          -  With the accompanying diseases or conditions affect the safety of patients during&#xD;
             normal enrollment or research&#xD;
&#xD;
          -  Active mental disorders or other mental disorders that affect the patients ability to&#xD;
             sign informed consent and understand&#xD;
&#xD;
          -  Uncontrolled active infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiade J Lu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Proton and Heavy Ion Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiade J Lu, M.D.</last_name>
    <phone>021-38296516</phone>
    <phone_ext>86</phone_ext>
    <email>jiade.lu@sphic.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Proton and Heavy Ion Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201321</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 25, 2020</study_first_submitted>
  <study_first_submitted_qc>August 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 2, 2020</study_first_posted>
  <last_update_submitted>August 28, 2020</last_update_submitted>
  <last_update_submitted_qc>August 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Proton and Heavy Ion Center</investigator_affiliation>
    <investigator_full_name>Jiade J. Lu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>Carbon-ion Radiotherapy</keyword>
  <keyword>Proton Radiotherapy</keyword>
  <keyword>Photon Radiotherapy</keyword>
  <keyword>Overall Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data will be uploaded by excel documents to share the IPD.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>On March, 2026</ipd_time_frame>
    <ipd_access_criteria>Excel document as the repository will be used for management.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

